Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Management

Background:

• Effective blood pressure (BP) control is crucial for reducing cardiovascular events in essential hypertension.
• Many patients struggle to reach BP goals with monotherapy, necessitating combination treatments.
• Current guidelines recommend drug combinations with complementary actions for moderate hypertension.

Purpose of the Study:

• To evaluate if switching to amlodipine plus telmisartan improves BP control in hypertensive patients inadequately managed by amlodipine plus valsartan or candesartan.
• To assess the efficacy of amlodipine/telmisartan combination compared to amlodipine/valsartan or amlodipine/candesartan.

Main Methods:

• Forty-seven essential hypertension patients uncontrolled on amlodipine/valsartan or amlodipine/candesartan were enrolled.
• Patients were switched to amlodipine (5 mg) plus telmisartan (40 mg).
• BP was monitored at baseline and at 4, 8, and 12 weeks post-switch.

Main Results:

• Switching to amlodipine/telmisartan resulted in a significant reduction in mean clinic systolic and diastolic BP (143.7/82.3 mmHg to 135.4/77.5 mmHg at 12 weeks).
• Central BP was significantly reduced by 11.8 mmHg in a subgroup of patients switched from valsartan.
• The amlodipine/telmisartan combination demonstrated superior BP lowering compared to the previous regimens.

Conclusions:

• Combination therapy with amlodipine and telmisartan offers a beneficial alternative for patients with uncontrolled essential hypertension.
• This regimen may provide more effective brachial and central BP control than amlodipine/valsartan or amlodipine/candesartan.
• Improved BP control with amlodipine/telmisartan could lead to more favorable cardiovascular outcomes.